1. Liang XL, Su YD, Li XB, Fu YB, Ma R, Yang R, Wu HL, Cui YR, Li Y*(corresponding author). Prognostic factors of long-term survival and conditional survival analysis in MPM patients treated with CRS+HIPEC: A retrospective study of two centers. Ann Surg Oncol. 2024; 32(4): 2912-2922.
2. Liang XL, Su YD, Fu YB, Li XB, Ma R, Yang R, Wu HL, Li Y*(corresponding author). Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: a single-center case-control study. Eur J Surg Oncol. 2024; 50(11): 108692.
3. Ji Z H, Zhao QD, Li Y*(corresponding author). The effects of HIPEC on survival of gastric cancer patients with peritoneal metastasis. J Surg Oncol. 2024; 130(6): 1190-1195.
4. Su YD, Ma R, Fu YB, Wu HL, Liang XL, Liu YT, Yu Y, Yang ZR, Li Y*(corresponding author). Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma. J Surg Oncol. 2024; 130(6): 1225-1234.
5. Liang XL, Li XB, Fu YB, Su YD, Ma R, Yang R, Wu HL, Li Y*(corresponding author). Research progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review. J Surg Oncol. 2024; 130(3): 533-542.
6. Liu G, Ji ZH, Li XB, An SL, Zhang YB, Li B, Yu Y, Zhao X, Yang R, Li Y*(corresponding author). Outcomes following cytoreductive surgery and hyperthermic intraoperative thoraco-abdominal chemotherapy with diaphragm resection for peritoneal carcinomatosis: A retrospective cohort study. Ann Surg Oncol. 2024; 31(2): 1058-1068.
7. Yang R, Su YD, Ma R, Li Y*(corresponding author). Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023; 49(1): 173-178.
8. Ji ZH, Yu Y, Liu G, An SL, Zhang YB, Li B, Li XB, Yan GJ, Li Y*(corresponding author). Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Eur J Surg Oncol, 2021; 47 (6): 1411-1419.
9. van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goéré D, González-Moreno S, Lehmann K, Li Y, Moran B, Morris DL, Piso P, Quadros CA, Rau B, Somashekhar SP, Sommariva A, van der Speeten K, Spiliotis J, Sugarbaker PH, Teo MCC, Verwaal VJ, Yonemura Y, Glehen O, de Hingh IHJT. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021; 47(11): 2888-2892.
10. Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, Yonemura Y, Li Y*(corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget. 2017; 8(33): 55657-55683.
11. Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, Morris D, Moran B, Gonzaletz-Moreno S, Deraco M, Piso P, Elias D, Batlett D, Ishibashi H, Mizumoto A, Verwaal V, Mahtem H. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016; 42(8): 1123-1131.
12. Fang M, Yuan JP, Peng CW, Li Y*(corresponding author). Collagen as a double-edged sword in tumor progression. Tumor Biol. 2014; 35(4): 2871-2882.
13. Zhong YJ, Shao LH, Li Y*(corresponding author). Cathepsin b-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol. 2013; 42(2): 373-383.
14. Fang M, Peng CW, Pang DW, Li Y*(corresponding author). Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol Med. 2012; 9(3): 151-163.
15. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Chen FL, Zhou YF, Xiong B, Yonemura Y, Li Y*(corresponding author). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011; 18(6): 1575-1581.
16. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol. 2011; 9(1): 32-43.
17. Chen C, Peng J, Xia HS, Yang GF, Wu QS, Chen LD, Zeng LB, Zhang ZL, Pang DW, Li Y*(corresponding author). Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials. 2009; 30(15): 2912-2918.
18. Huang W, Ding Y, Miao Y, Liu MZ, Li Y*(co-corresponding author), Yang GF. Synthesis and antitumor activity of novel dithiocarbamate substituted chromones. Eur J Med Chem. 2009; 44(9): 3687-3696.
19. Chen LD, Liu J, Yu XF, He M, Pei XF, Tang ZY, Wang QQ, Pang DW, Li Y*(corresponding author). The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials. 2008; 29(31): 4170-4176.
20. Al-Shammaa HAH, Li Y*(corresponding author), Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008; 14(8): 1159-1166.
21. Zheng F, Shi XW, Yang GF, Gong LL, Yuan HY, Cui YJ, Wang Y, Du YM, Li Y* (corresponding author). Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study. Life Sci. 2007; 80(4): 388-396.
22. Huang W, Liu MZ, Li Y*(corresponding author), Tan Y, Yang GF. Design, synthesis, and antitumor activity of novel chromone and aurone derivatives. Bio Med Chem. 2007; 15(15): 5191-5197.
23. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol. 2004; 130(8): 460-468.
24. Li Y, Tang ZY, Ye SL, Liu BB, Liu YK, Chen J, Xue Q*. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003; 129(1): 43-51.
25. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH*. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2001; 7(5): 630-636.
